The Prostate SPORE Developmental Research Program operates under the direction of the Administrative Core. The SPORE sets aside $150,000 each year (plus Institutional support) to fund 4-5 feasibility projects to generate data that will enable the investigator to apply for extramural funds. In January of each year a request for pilot projects is sent out to all members of the Cancer Centers at Northwestern University and the University of Chicago. There is an established process for peer review of pilot projects by an ad hoc review committee. The SPORE Executive Committee takes priority scores and makes the final funding decision. The process is flexible, in that pilot projects can be elevated to replace full SPORE projects and pilot projects can be terminated if progress is not satisfactory. For example, Project 4 (PI: Bergan and Catalona) and Project 3 (PI: Weichselbaum and Stadler) were both pilot projects that were elevated to full project status based on significant progress made. And Project 2 (PI: Crawford, Gapstur and Lee) has also been elevated from a pilot project. Additionally, an investigator may submit a pilot project at any time to the SPORE Director. It is reviewed by the ad hoc committee and if favorably reviewed and if adequate funds exist, it may receive funding. Therefore, the Developmental Research Program enables the Prostate SPORE to expand investigator participation to bring more investigators into the field to maximize our research efforts on prostate cancer. A detailed description of pilot projects is described in Section XII of the application

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Pascal, Laura E; Masoodi, Khalid Z; O'Malley, Katherine J et al. (2015) 5?-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol 193:1388-93
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Grin, Boris; Loeb, Stacy; Roehl, Kim et al. (2015) A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease. BJU Int 115:101-5
Helenowski, Irene B; Demirtas, Hakan (2014) Multiple imputation of continuous data via a semiparametric probability integral transformation. J Biopharm Stat 24:359-77
Venkatasubramanian, Palamadai N; Brendler, Charles B; Plunkett, Beth A et al. (2014) Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study. Prostate 74:326-35
Adams, Daniel L; Martin, Stuart S; Alpaugh, R Katherine et al. (2014) Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111:3514-9
Ai, J; Pascal, L E; O'Malley, K J et al. (2014) Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene 33:2286-94
Pavese, Janet M; Ogden, Irene M; Voll, Eric A et al. (2014) Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One 9:e102289
Kregel, Steven; Szmulewitz, Russell Z; Vander Griend, Donald J (2014) The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 74:1530-43
Wu, L; Runkle, C; Jin, H-J et al. (2014) CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 33:504-13

Showing the most recent 10 out of 160 publications